



Corrigendum: The Economic Impact of a Switch From Prescription-Only to Non-prescription Drugs in Italy

Monica Hildegard Otto^{1,2*}, Carla Pillarella³ and Claudio Jommi^{1,4}

OPEN ACCESS

Edited and reviewed by:

Philippe Van Wilder,
Free University of Brussels, Belgium

*Correspondence:

Monica Hildegard Otto
monica.otto@unibocconi.it

Specialty section:

This article was submitted to
Pharmaceutical Medicine and
Outcomes Research,
a section of the journal
Frontiers in Pharmacology

Received: 24 December 2018

Accepted: 05 February 2019

Published: 05 March 2019

Citation:

Otto MH, Pillarella C and Jommi C
(2019) Corrigendum: The Economic
Impact of a Switch From
Prescription-Only to Non-prescription
Drugs in Italy.
Front. Pharmacol. 10:129.
doi: 10.3389/fphar.2019.00129

¹ Centre for Research on Health and Social Care Management (CERGAS) SDA Bocconi School of Management, Milan, Italy,

² Department of Social and Political Sciences, Bocconi University, Milan, Italy, ³ Federchimica Assosalute, Milan, Italy,

⁴ Department of Pharmaceutical Sciences, Università del Piemonte Orientale, Novara, Italy

Keywords: switch, OTC, economic impact, self-medication, pharmaceutical expenditure

A Corrigendum on

The Economic Impact of a Switch From Prescription-Only to Non-prescription Drugs in Italy.
by Otto, M. H., Pillarella, C., and Jommi, C. (2018). *Front. Pharmacol.* 9:1069.
doi: 10.3389/fphar.2018.01069

In the original article, there was a mistake in **Table 2** as published. The item “NON prescription (C and Cbis)”, should have been listed as “NON prescription (C)”. Additionally, there was a mistake in **Figure 1** as published. The horizontal axis interval was incorrect, therefore rendering the labels ineligible. The corrected **Table 2** and **Figure 1** appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Copyright © 2019 Otto, Pillarella and Jommi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

TABLE 2 | Market of switchable drugs (2015).

Items	Switchable market	Overall market 2015	%
Volumes (thousands of units)	133,567	1,662,800	8.0%
Reimbursed prescription only (A)	95,965	1,336,523	7.2%
NON Reimbursed prescription only (C)	24,529	251,482	9.8%
NON prescription (C)	13,073	74,795	17.5%
Expenditure (million Euro)	1,677	15,979	10.5%
Reimbursed prescription only (A)	1,198	12,295	9.7%
NON Reimbursed prescription only (C)	316	3,038	10.4%
NON prescription (C)	162	646	25.1%

Source: own elaboration on IQVIA data.




FIGURE 1 | Market of switchable drugs by priority (2015). *Classified as OTC at least in 3 out of 4 main European Countries.